U.S. stock futures traded with little net change on Wednesday as investors positioned themselves ahead of a key Federal Reserve interest rate decision and followed coverage of a preliminary Middle East peace agreement. By 08:40 ET (012:40 GMT), the Dow futures contract fell 0.1%, S&P 500 futures gained 0.1%, and Nasdaq 100 futures were up 0.5%.
In premarket activity, healthcare and technology names drew notable attention, while market participants also reacted to analyst moves and merger developments announced overnight. The most pronounced premarket swings were concentrated among a handful of companies spanning biotech, semiconductor equipment, shipping and defense contracting.
UniQure was the day’s most dramatic mover. The gene therapy developer’s stock surged 67.5% after the company said the U.S. Food and Drug Administration had agreed that three-year data from its Phase I/II study of AMT-130 could serve as the primary basis for a Biologics License Application seeking accelerated approval for Huntington’s disease. The company framed the FDA’s agreement as material to the potential regulatory pathway for its therapy.
Aehr Test Systems also posted a strong premarket gain, jumping 11% following an announcement that it had secured a follow-on production order for a fully automated FOX-XP wafer-level burn-in system from a major silicon photonics customer. The maker of semiconductor test equipment said the system is expected to be delivered within the next six months.
Snap remained under pressure after plunging 9.6% in the prior session. The decline followed the launch of the company’s standalone augmented reality glasses, called "SPECS," which investors appeared skeptical about in terms of near-term commercial prospects.
Genco Shipping & Trading rose 8% after Diana Shipping increased its acquisition proposal to $27.34 per share, comprised of cash and stock. Diana characterized the revised offer as a substantial premium to Genco’s share price before its initial proposal.
T1 Energy gained 1.9% after Bernstein SocGen Group initiated coverage with a Market Perform rating and a $9 price target, citing growth opportunities alongside ongoing legal risks for the solar and battery storage company.
Leidos Holdings slipped 1.3% after BofA Securities downgraded the defense and information technology contractor to Neutral from Buy and cut its price target to $125 from $200.
The premarket action underscored how a mix of regulatory updates, equipment orders, corporate proposals and analyst decisions can drive outsized moves in single stocks even as broad market futures remain muted ahead of major macroeconomic catalysts.